Application of cell-free DNA for genomic tumor profiling: a feasibility study.

ABSTRACT:

Purpose

Access to genomic tumor material is required to select patients for targeted therapies. However, tissue biopsies are not always feasible and therefore circulating cell-free DNA (cfDNA) has emerged as an alternative. Here we investigate the utility of cfDNA for genomic tumor profiling in the phase I setting.

Study design

Peripheral blood was collected from patients with advanced solid cancers eligible for phase I treatment. Patients failing the initial tissue biopsy due to inaccessible lesions or insufficient tumor cellularity (<10%) were included in the study. Genomic profiling of cfDNA including whole exome sequencing (WES) and somatic copy number alterations (SCNAs) analysis (OncoScan).

Results

Plasma cfDNA was pro- and retrospectively profiled from 24 and 2

SUBMITTER: Ahlborn LB 

PROVIDER: S-EPMC6402712 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature